塞来昔布

Name: 塞来昔布
Brand: 济南圣和化工有限公司

CAS 169590-42-5C17H14F3N3O2SMW 381.4

济南圣和化工主营供应塞来昔布（CAS 169590-42-5），归类于医药中间体及原料药，分子式 C17H14F3N3O2S，分子量 381.4。我们面向国内化工贸易与生产企业提供稳定的现货供应，报价响应快，支持对公转账并可开具增值税发票。

产品概览

CAS号	169590-42-5
分子式	C17H14F3N3O2S
分子量	381.4
熔点	157-159
沸点	529.0±60.0
LogP	3.53
纯度	按批次COA提供(不公开发布)
包装	按订单/批次确认(不公开发布)
应用领域	医药中间体及原料药
类别	医药中间体及原料药

应用领域

医药中间体及原料药

塞来昔布主要应用于医药中间体及原料药。具体使用工况下的添加量与规格要求，欢迎与技术团队沟通确认。

包装与储存

包装规格按订单/批次确认(不公开发布)

纯度规格按批次COA提供(不公开发布)

储存条件密封、阴凉干燥处保存

运输常规化工运输

样品可协商提供

交期现货/按订单安排

供货能力：塞来昔布备有现货，包装形式为按订单/批次确认(不公开发布)。我们支持对公转账并开具增值税发票，山东省内可安排快速配送，省外按物流时效发货，具体请联系 info@591daili.com。

质量与文件

每批产品随货提供 COA（分析证书）；可按需提供 MSDS/技术数据表及第三方检测报告。纯度与包装以批次 COA 及订单确认为准。

关于供应商

作为化工原料供应服务商，济南圣和化工有限公司长期服务于化工贸易、食品添加、医药中间体、日化原料等行业的采购需求。除塞来昔布外，您还可以在站内按 CAS 号或产品分类检索更多品类，获取规格与报价。

常见问题

塞来昔布的 CAS 号是多少？

塞来昔布的 CAS 号为 169590-42-5。

该产品的纯度和包装规格是什么？

常规纯度规格为按批次COA提供(不公开发布)，包装为按订单/批次确认(不公开发布)，随货提供 COA。

塞来昔布有什么用途？

主要应用于医药中间体及原料药。

如何购买或获取报价？

请发送邮件至 info@591daili.com 或通过 WhatsApp 联系，注明产品名称、CAS 号与需求数量，一个工作日内回复报价。供应商：济南圣和化工有限公司。

PubChem 公开数据

Description

Celecoxib · CAS 169590-42-5 · C17H14F3N3O2S. UNII JCX84Q7J1L. Boiling Point: 529.0±60.0; Melting Point: 157-159; Melting Point: 157-159 °C.

Identification

CAS Registry Number	169590-42-5
PubChem CID	2662
Molecular formula	C17H14F3N3O2S
IUPAC name	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
UNII (FDA)	JCX84Q7J1L

Computed Descriptors

Molecular Weight	381.4
XLogP3	3.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	3
Exact Mass	381.07588236
Monoisotopic Mass	381.07588236
Topological Polar Surface Area	86.4
Heavy Atom Count	26
Formal Charge	0

Physical & Chemical Properties

Boiling Point	529.0±60.0
Melting Point	157-159
Melting Point	157-159 °C
Melting Point	101.7 - 103.9 °C
LogP	3.53
LogP	3.42
Dissociation Constants	11.1

Physical description & handling notes

Solid
Pale yellow solid
Poorly soluble
Stable under recommended storage conditions.
Hazardous decomposition products formed under fire conditions: Carbon oxides, Nitrogen oxides (NOx), Sulfur oxides, Hydrogen fluoride.
pKa = 11.1 (sulfonamide moiety)

GHS Hazard Classification

Reported hazard statements	H317 (11.9%), H319 (12.6%), H360 (82.4%), H401, H411

H317 (11.9%): May cause an allergic skin reaction [Warning Sensitization, Skin]

H319 (12.6%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

Documented Uses

Use (kg; approx.) in Germany (2009): >5000
Use (kg; exact) in Germany (2009): 5262
Consumption (g per capita; approx.) in Germany (2009): 0.0611
Consumption (g per capita; exact) in Germany (2009): 0.0643
Consumption (g per capita) in the USA (2002): 0.557
For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis

Synonyms

celecoxib; 169590-42-5; Celebrex; Celebra; Onsenal; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; SC-58635; 184007-95-2; YM 177; p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Celecoxibum; DTXSID0022777; SC58635; DFN15; JCX84Q7J1L

Frequently Asked Questions

What are the CAS number and molecular formula of Celecoxib?

CAS 169590-42-5; molecular formula C17H14F3N3O2S; molecular weight — g/mol.

What other names is Celecoxib known by?

celecoxib, 169590-42-5, Celebrex, Celebra, Onsenal, 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE.

Is Celecoxib classified as hazardous?

Hazard statements reported: H317, H319, H360, H401, H411.

What are the key physical properties of Celecoxib?

Boiling Point: 529.0±60.0; Melting Point: 157-159; Melting Point: 157-159 °C; Melting Point: 101.7 - 103.9 °C.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.